



Logistics and Supply Chain MultiTech R&D Centre  
物流及供應鏈多元技術研發中心

For Immediate Release

## **LSCM collaborates with Hong Kong Institute of Biotechnology in developing an innovative Digital Supply Chain Logistics Management Platform for Cell and Gene Therapy GMP Operation**

*Enhancing operational effectiveness while paving the way  
for strategic expansion into the Greater Bay Area*

**25 Sep 2025, Hong Kong** — Logistics and Supply Chain MultiTech R&D Centre (LSCM) today announced a successful collaboration with the Hong Kong Institute of Biotechnology (HKIB) to develop a Digital Supply Chain Logistics Management Platform for Cell and Gene Therapy (CGT) Good Manufacturing Practice (GMP) operation. The platform is tailored to optimise the operational workflows of CGT product manufacturing and pave the way for market expansion into the Greater Bay Area (GBA). This collaboration demonstrates LSCM's dedication to fostering the development of different industries in Hong Kong with cutting-edge technologies while bringing meaningful benefits to the biotech industry and to the community.

Cell and Gene Therapy (CGT) represents a game-changing approach for treating diseases once deemed incurable, such as cancers, autoimmune disorders, and genetic diseases. As a biotech trailblazer in Hong Kong, HKIB Advanced Therapy Products (ATP) GMP Centre (the Centre) stands at the forefront of CGT innovation. Its PIC/S GMP certified ATP GMP facility serves as the essential gateway to advance academic CGT research to clinical realities.

The Centre currently manufactures Chimeric Antigen Receptor T-cell (CAR-T) for clinical trials. CAR-T is a living medicine and a type of ATP for CGT where patients' own immune cells are engineered to treat their own disease. With local manufacturing becoming available through HKIB, the turnaround time for CAR-T cell therapy can be significantly reduced at a much lower cost.

A primary challenge in ATP manufacturing is the complexity of the supply chain, with particular obstacles in visibility, traceability, data confidentiality, cross-party efficiency, and adherence to regulatory requirements. Synchronisation and agility across all elements of the supply chain is critical, as precise order fulfilment is essential to patient outcomes. While ERP solutions are available, needs remain unmet as those specialised for ATP GMP operations are mainly designed for the US or EU markets, resulting in regulatory, linguistic, and security challenges for implementation in Hong Kong and the GBA. To address these issues, LSCM and HKIB have developed an end-to-end platform offering comprehensive automation and digitisation capabilities throughout the entire ATP manufacturing process for Hong Kong, the GBA, and beyond.

By leveraging the digital platform developed by LSCM to streamline processes and handle extensive documentations, HKIB ATP GMP Centre can increase manufacturing capabilities to meet the growing clinical trial case demands. For instance, it digitises up to 750 pages of documents per clinical case, enabling workforce optimisation, offering faster, easier, and sustainable operation. The Centre's internal testing has also demonstrated significant efficiency enhancement, saving at least 7 hours per CAR-T manufacturing cycle, alongside the improvements in warehouse management, traceability, quality control, equipment maintenance, and manpower arrangement. These enhancements collectively reduce the level of manual involvement across operations.



## Logistics and Supply Chain MultiTech R&D Centre 物流及供應鏈多元技術研發中心

Moreover, the machine translation tailored to ATP that is incorporated into the platform enables the translation of ATP documents and forms between Chinese and English, boosting efficiencies in cross-border communication and integration, collaboration and knowledge sharing. Additionally, the platform's real-time updating function, together with the scheduling and logistics capabilities, enable smoother and more effective coordination to meet the increased manufacturing demands.

LSCM also utilises advanced cloud technologies to enhance the platform with robust security, ensuring data immutability and protection against unauthorised access, thereby enhancing data privacy and integrity. Its input validation reduces errors and manual effort in data entry, safeguarding patients' well-being and treatment integrity. Additionally, it features warehouse management function to comply with SOPs, seamless material stock tracking, equipment maintenance, and integrates personnel training and calibration records for timely actions.

"HKIB is pleased to collaborate with LSCM, which has consistently demonstrated professionalism and deep engagement throughout the R&D process. Their team understood our needs and ATP GMP requirements, and also the regulatory standards; showing a strong commitment to technology development and compliance," said **Dr. Gina Jiang, Managing Director of HKIB**. "This specialised platform developed by LSCM not only has the potential to streamline complex workflows of ATP manufacturing, it can also be an effective tool to optimise workforce and a prelude to automation. We are confident that this collaboration will accelerate advancements in cell and gene therapy manufacturing and delivery, laying a strong base for a sustainable and successful future."

**Mr Simon Wong, Chief Executive Officer of LSCM**, said, "We're proud to provide technology support to HKIB in facilitating the digitalisation of cell and gene therapy manufacturing. By automating and digitising the entire ATP production workflow, starting with CAR-T, the system lays the foundation for future expansion while the positive feedback from HKIB affirms the platform's value. We look forward to strengthening our partnership with HKIB and further contributing to the development of biotech industry in Hong Kong and the GBA. This also aligns with the Government's initiatives in developing the new quality productive forces."

Looking ahead, LSCM anticipates further collaboration with HKIB to continue advancing the digital transformation of cell and gene therapy manufacturing across Hong Kong and the GBA. As other digitalisation initiatives, including warehouse digitalisation and chain of custody development, are anticipated, this partnership stands as a meaningful milestone in propelling Hong Kong's biotech development and demonstrating the pivotal role of the technology R&D in underpinning and positioning Hong Kong at the forefront of biomedical innovation.

### About HKIB ATP GMP Centre

The Hong Kong Institute of Biotechnology (HKIB) was established in 1988, funded by the generous donation of The Royal Hong Kong Jockey Club (renamed The Hong Kong Jockey Club in 1997). In 2000, HKIB becomes an affiliate of The Chinese University of Hong Kong. The HKIB ATP GMP Centre is a collaboration between The Chinese University of Hong Kong, The Hong Kong Science and Technology Parks Corporation (HKSTP) and HKIB. It brings together top-notch Hong Kong talent in pharmaceutical industry and academia in Cell and Gene Therapy, and provides a state-of-the-art certified GMP facility for the production of ATPs. By offering a full value chain from bench to bedside, the Centre greatly strengthens Hong Kong's competitive advantages and positions the city as a major global hub for strategic development in biotech and health sciences enterprises.

More information on the HKIB ATP GMP Centre: <https://atp.hkib.org.hk>



**Logistics and Supply Chain MultiTech R&D Centre**  
**物流及供應鏈多元技術研發中心**

### About LSCM

Logistics and Supply Chain MultiTech R&D Centre (LSCM) was founded in 2006, with funding from the Innovation and Technology Fund of The Government of the Hong Kong SAR, and is co-hosted by the University of Hong Kong, the Chinese University of Hong Kong and the Hong Kong University of Science and Technology. It aims to strengthen the local logistics sector and related industries by providing a one-stop resource for applied research and technology transfer, and to reinforce cooperation between the industry and research institutes to bring about meaningful and significant benefits to the industry and the community. For more information, please visit [www.lscm.hk](http://www.lscm.hk).

– End –

### For media enquiries, please contact:

#### IPR Ogilvy

Shelley Li / Edward Lai

Tel: (852) 6013 7485 / 9466 2465

Email: [shelley.li@iprogilvy.com](mailto:shelley.li@iprogilvy.com) /  
[edward.lai@iprogilvy.com](mailto:edward.lai@iprogilvy.com)

#### LSCM

Wendy Fung / Eliza Cheng

Tel: (852) 3973 6213 / 3973 6210

Email: [wfung@lscm.hk](mailto:wfung@lscm.hk) /  
[echeng@lscm.hk](mailto:echeng@lscm.hk)

### Photo Captions

Photo 1:



HKIB Advanced Therapy Products (ATP) GMP Centre advances academic CGT research to clinical realities.




Logistics and Supply Chain MultiTech R&D Centre  
物流及供應鏈多元技術研發中心

Photo 2:



The Centre currently manufactures Chimeric Antigen Receptor T-cell (CAR-T) for clinical trials.

Photo 3:



LSCM and HKIB collaborated to develop the Digital Supply Chain Logistics Management Platform for CGT GMP operation. It streamlines the complex workflows of ATP manufacturing, optimising workforce and foster automation.